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Abstract
Rationale: In life-threatening coronavirus disease (COVID-19),
corticosteroids reduce mortality, suggesting that immune responses
have a causal role in death. Whether this deleterious inflammation is
primarily a direct reaction to the presence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) or an independent
immunopathologic process is unknown.
Objectives: To determine SARS-CoV-2 organotropism and organ-
specific inflammatory responses and the relationships among viral
presence, inflammation, and organ injury.
Methods: Tissue was acquired from 11 detailed postmortem
examinations. SARS-CoV-2 organotropism was mapped by using
multiplex PCR and sequencing, with cellular resolution achieved by in
situviral S (spike)proteindetection.Histologicevidenceof inflammation
was quantified from 37 anatomic sites, and the pulmonary immune
response was characterized by using multiplex immunofluorescence.
Measurements and Main Results:Multiple aberrant immune
responses in fatal COVID-19 were found, principally involving
the lung and reticuloendothelial system, and these were not
clearly topologically associated with the virus. Inflammation
and organ dysfunction did not map to the tissue and cellular
distribution of SARS-CoV-2 RNA and protein between or
within tissues. An arteritis was identified in the lung, which
was further characterized as a monocyte/myeloid-rich vasculitis,
and occurred together with an influx of macrophage/monocyte-
lineage cells into the pulmonary parenchyma. In addition,
stereotyped abnormal reticuloendothelial responses, including
excessive reactive plasmacytosis and iron-laden macrophages,
were present and dissociated from viral presence in lymphoid
tissues.
Conclusions: Tissue-specific immunopathology occurs in
COVID-19, implicating a significant component of the immune-
mediated, virus-independent immunopathologic process as a
primary mechanism in severe disease. Our data highlight novel
immunopathologic mechanisms and validate ongoing and
future efforts to therapeutically target aberrant macrophage and
plasma-cell responses as well as promote pathogen tolerance in
COVID-19.
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Inflammation, organ injury, and death
due to viral infection can occur as a result
of direct viral cytotoxicity, collateral damage
from an appropriate pathogen-driven
immune response, or an aberrant
response precipitated by the pathogen,
causing an immunopathology (1).
Resilience to infectious disease is
frequently thought of as best achieved
through resistance (controlling the
pathogen load to prevent organ injury),
but the emerging concept of tolerance
(preventing organ injury and inflammation
despite the presence of a pathogen)
is equally valid (2). In this context,
tolerance could involve restricting the
production of injurious inflammatory
effectors or moderating pro- and
antiinflammatory signaling downstream
of pathogen sensing to reduce
immunopathology (3, 4).
Hyperinflammation is a recognized
component of coronavirus disease (COVID-
19) and is associated with organ
dysfunction, disease severity, and death
(5–7). Fatal COVID-19 most often occurs
with critical impairment of oxygenation,
and treatment with corticosteroids has
been robustly demonstrated to reduce
mortality in these circumstances (8–13).
This suggests that pulmonary inflammation
has a causal role in death, but it remains
unknown whether this inflammation
is a direct response to the presence of
severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) or an
independent immunopathologic process.
Human immunology studies focusing on
peripheral blood (7, 14) and BAL fluid
(BALF) (15) are revealing fundamental
changes during COVID-19, but these
approaches risk underestimating the
immune changes within actual pulmonary
tissue, and so immunophenotyping at
a whole-lung level in severe COVID-19
is essential. Although COVID-19 is
principally thought of as a pulmonary
disease, increasing evidence shows that
SARS-CoV-2 also has extrapulmonary
tissue tropism (16) and that dysfunction
of multiple organs occurs in COVID-19
(17). The relationship among the
presence of the virus, evidence of organ
injury, and the associated immune
response at a tissue and cellular level
remains poorly defined.
To better understand the
pathogen–host interaction and the
immunologic consequences of COVID-19,
we present a multiparameter tissue
survey of fatal COVID-19. We sought
to characterize and determine the
relationships between viral organotropism
and organ-specific immune responses.
Some of the results of these studies were




For detailed methods, see the online
supplement.
Postmortem Examinations
Postmortem examinations were conducted
in a biosafety level 3 postmortem facility on
patients with premortem PCR-confirmed
SARS-CoV-2 infection and evidence of
lower respiratory tract disease at a median
of 19.3 hours after death (interquartile
range, 4.6–20.2). Thirty-seven tissue sites
were systematically sampled, after a
standardized protocol, for histologic
and RNA analyses, including 23 sites
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At a Glance Commentary
Scientific Knowledge on the
Subject: Inflammation is implicated
in respiratory failure and death in
severe coronavirus disease (COVID-
19). The relationships between viral
organotropism and organ-specific
inflammatory responses have not been
characterized, so it is unknown
whether inflammation is a direct
response to the presence of severe acute
respiratory syndrome coronavirus 2
(SARS-CoV-2) or whether virus-
independent immunopathologic
processes contribute.
What This Study Adds to the Field:
A disconnect between viral presence
and inflammation implicates
immunopathology as a primary







and plasma-cell responses in the
reticuloendothelial system, findings
that validate ongoing investigations of
immunomodulatory and antiinflammatory
drugs in severe COVID-19.
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from the respiratory tract (see Figure E1
in the online supplement). Samples were
fixed in formalin or treated with TRIzol
(Life Technologies), snap frozen, and
stored at 2808C. Ethical approval was
granted by the East of Scotland Research
Ethics Service (16/ES/0084). Full clinical
and radiologic details of our patient
cohort are shown in Table 1, Figure E2,




(FFPE) tissue blocks were processed and
hematoxylin and eosin–stained after a
standardized process in the hospital
diagnostic pathology laboratory (18).
Slides were reviewed by a group of
specialist histopathologists who scored
inflammation semiquantitatively (none = 0,
mild = 1, moderate = 2, severe = 3). For
immunophenotyping, multiplexed
immunofluorescence on deparaffinized
rehydrated FFPE slides was performed
using combinations of primary antibodies
against CD34, CD68, MRP8, CD4, CD8,
and CD20, labeled with Tyramide
Signal Amplification (TSA)-conjugated
fluorophores, with antibody removal
between steps. Images were captured
using a Vectra Polaris slide scanner
(Akoya Biosciences). Control tissue for
immunophenotyping was obtained
from lung cancer–resection specimens.
Uninflamed lung tissue distinct from
the site of carcinoma was used for
immunofluorescence.
Viral RNA and Protein Detection
Total RNA was extracted at biosafety
level 3 from homogenized TRIzol-treated
tissue. Samples were DNase-treated and
complementary DNA–synthesized before
amplification of SARS-CoV-2 by the ARTIC
Network protocol using the multiplexed
primer scheme version 3. Purified PCR
products were processed, sequenced, and
analyzed as per the online supplement. The
postmortem interval was not associated with
the number of tissue samples that were
SARS-CoV-2–positive as determined by
PCR results postmortem (Figure E3).
Deparaffinized, rehydrated FFPE slides were
examined for the presence of the SARS-CoV-2 S
(spike) protein, with this being performed
on randomly selected PCR-confirmed SARS-
CoV-2–positive tissue from four patients,
with or without additional cell markers
(CD68 [mononuclear phagocytes], AE1/3
[epithelium], and CD105 [endothelium]) to
detect viral presence.
Results
Mapping SARS-CoV-2 Distribution to
Tissue Inflammation
To create a detailed tissue atlas of fatal
COVID-19, we sampled 37 distinct
anatomic tissue sites at autopsy to identify
viral RNA distribution and host immune
responses (Figure E1). We detected
SARS-CoV-2 RNA across all sampled
organs and tissue sites, most frequently in
the respiratory tract but also in the
gastrointestinal tract, heart, and muscle
and less often in the liver, kidney, and
other organs (Figures 1A and 1B).
Despite all sampled organs having the
potential to contain SARS-CoV-2 RNA,
we observed substantial interpatient
variation in the tissue sites involved
(Figure 1B). The time from illness
onset to death did not correlate
with the number of PCR-confirmed
SARS-CoV-2–positive organs (Figures 1B
and E3). Results from multiplex PCR
were confirmed to map to the SARS-
CoV-2 genome by sequencing (Figures
1C and 1D), significantly increasing
confidence in these data compared with
data from a PCR-only approach. Viral
subgenomic mRNA (most commonly
from the nucleocapsid gene) was also
detected from PCR-confirmed SARS-
CoV-2–positive sites, indicating that
active viral RNA synthesis had occurred
(Figure E4).
As analysis of SARS-CoV-2 RNA
confirmed presence in numerous
organs, detailed tissue analysis was
undertaken on every patient to determine
the associated pathologic consequences
and immune responses. In contrast to
the distribution of viral RNA, this
analysis indicated that the lung and
reticuloendothelial system were the
exclusive sites of an extensive inflammatory
response (Figure 1A). Extrapulmonary
sites with the virus present, and with
evidence of viral transcription, did not
have substantial local inflammation.
To better resolve this organ-specific
pathogen–host interaction at a spatial and
cellular level, the presence of SARS-CoV-2
S protein was evaluated on randomly
selected PCR-confirmed SARS-CoV-2–
positive tissues. Consistent with the latest
reports on tissue expression of SARS-CoV-2
entry factors (19), S protein was found
predominantly within epithelia of the
aerorespiratory tract, gastrointestinal tract,
liver, and kidney, with limited presence
within macrophages (CD681 cells) and
endothelial cells (CD1051 cells) of lung
tissue (Figures 1E and 1F). S protein was
only rarely detected in some of the PCR-
confirmed SARS-CoV-2–negative tissues




Illness duration, d 23.6610.0
Clinical and radiologic features
Hypoxic respiratory failure 11 (100)
Bacterial pneumonia
Microbiologically confirmed 4 (36.4)
Suspected 6 (54.5)
Thoracic radiology
Pulmonary GGO 11 (100)
Pulmonary embolism 3 (27.3)
Supportive care
Supplemental oxygen 11 (100)
Invasive mechanical ventilation 4 (36.4)
Duration, d* 18.36 7.8
Vasopressors 4 (36.4)
Renal replacement therapy 3 (27.3)
Definition of abbreviation: GGO=ground-glass opacification.
Data are presented as the mean6SD or absolute number (% of total).
*Time from intubation to death.
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Figure 1. Mapping severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) organotropism and cellular distribution in fatal coronavirus disease
(COVID-19) in relation to tissue inflammation. (A) Distribution of SARS-CoV-2 RNA for all patients was determined by using multiplex PCR (color intensity
denotes frequency of detectable RNA; dotted line on legend denotes maximal frequency within the patient cohort) (n=11). The extent of organ-specific
inflammation was assessed semiquantitatively (0–3; no inflammation [0] to severe inflammatory changes [3]), with aggregate scores visualized (n=11).
(B) Distribution of individual-patient (patients A–K) viral RNA presence within organs plotted against the time interval between illness onset and death
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tested and was not found in postmortem
tissues from patients who did not have
SARS-CoV-2 infection (data not shown).
Although SARS-CoV-2 S-protein
expression within lung alveolar epithelial
cells was patchy in nature, consistent with
possible aspiration or inhalation of virus
from the upper respiratory tract (20),
expression at nonpulmonary sites
frequently revealed several well-demarcated
areas of confluent SARS-CoV-2 S-protein
expression within adjacent cells,
surrounded by cells with no detectable
protein (Figure 1E). These “foci of
infection,” with numerous affected
cells adjacent to unaffected cells, are
suggestive of cell-to-cell spread, as
reported in other coronavirus and
respiratory viruses (21, 22).
Overall, we observed minimal evidence
of acute inflammation in other organs
(Figure 1A). Background changes of
chronic disease were common, reflecting
preexisting comorbidities. Expected organ
injury commensurate with severity of
systemic illness was also present (e.g., renal
acute tubular necrosis in mechanically
ventilated patients; Table E3). Detectable
viral RNA in the kidney (n= 4 detectable),
liver (n= 4), and gastrointestinal
tract (n= 7) was not associated with
inflammation scores or with biochemical
evidence of acute kidney injury, peak ALT
(alanine aminotransferase) measurement,
or enteric symptoms, respectively (Figure
E5). No acute tissue abnormalities were
identified in the gastrointestinal tract or
endocrine organs, and no cases of
myocarditis were identified despite frequent
detection of viral RNA within these tissues
(Table E3). Importantly, the presence of
viral protein within the kidney (n= 4
assessed), intestine (n= 3), and liver
(n= 2) was not associated with a localized
inflammatory response adjacent to the
infected cells (Figures 1E and 1F and E6).
Pulmonary Inflammation and
Relationship to SARS-CoV-2
Pulmonary tissue was highly abnormal,
with diffuse alveolar damage (DAD; the
pathologic hallmark of acute respiratory
distress syndrome), thrombosis, and
bronchopneumonia being frequent but
variable findings (Figure 2A). Unexpectedly,
the geographic distribution of SARS-CoV-2
RNA presence within the lung was not
linearly associated with pulmonary
inflammatory changes within our cohort, as
DAD and bronchopneumonia were both
observed in sections of lung with and
without detectable virus. In one patient
(patient I), the virus could be detected in
the absence of significant pulmonary
inflammation. These findings strongly
suggest that virus-independent
immunopathology, rather than direct
viral cytotoxicity, is one of the
primary mechanisms underlying severe
COVID-19.
Consistent with results of recent
reports, we found that pulmonary thrombi
were present in multiple patients (8 of 11;
small vessel only n= 1, large vessel only
n= 2, large and small vessel n= 5)
(Figure 2A). A patchy but striking
mononuclear-cell vasculitis predominantly
affecting intima of small/medium-sized
pulmonary arteries was also observed in 4
of 11 cases (Figure 2B). This pulmonary
arterial immune infiltrate was further
characterized in two patients (A and C)
by using multiplex immunofluorescence
(Figures 2C and 2D). Unexpectedly,
MRP81 mononuclear cells were the
predominant infiltrating population
accompanied by a mixed population of
CD41 and CD81 T cells and macrophages
(Figures 2C and 2D). Inspection of 40
inflamed vessels from the same patients
did not identify SARS-CoV-2 S protein
within the surface endothelium
(data not shown). No vasculitis was
evident in any of the other organs
studied.
Increased CD81 T cells and
reduced resident lung macrophages have
recently been reported using single-
cell transcriptomics on BALF cells
(15). However, this approach risks
underestimating pathophysiologic and
immune changes within the nonluminal
pulmonary compartment. To understand
the immune response at a whole-lung level
multiplex immunophenotyping was
undertaken on pulmonary tissue (Figures
3A–3G and E7). Our analysis revealed that
the greatest increase in immune cells was
predominantly within parenchymal regions
rather than within vascular/perivascular
areas (Figures 3F and 3G). This showed
that the largest relative increases
were within the mononuclear phagocyte
compartment (CD681/MRP82
macrophages, then CD681/MRP81
monocytic cells), followed by CD81 and
then CD41 T cells. Smaller increases in
CD201 cells and MRP81/CD682 cells were
also observed.








Figure 1. (Continued). compared with organ-specific inflammation scores for each patient. *Denotes
invasive mechanical ventilation. (C and D) Multiplex PCR–confirmed SARS-CoV-2–positive samples
were confirmed by sequencing, with the proportion of the SARS-CoV-2 genome mapped calculated
(C) and a representative sequence-coverage map of the respiratory tract of one patient shown (D).
(E and F) Tissue and cellular distribution of SARS-CoV-2 S (spike) protein was evaluated by using
immunohistochemistry and multiplex immunofluorescence on randomly selected PCR-confirmed
SARS-CoV-2–positive formalin-fixed, paraffin-embedded tissue (n=4 patients). (E) Representative
images demonstrate the tissue distribution of S protein within the nasal mucosa, bronchial epithelium,
small-bowel enterocytes, distal biliary epithelium within the liver, and distal renal tubular epithelium. (F)
Within the lung, cellular localization of S protein is demonstrated within the alveolar epithelium (AE1/3)
and is rarely demonstrated in macrophages (CD68) or in the endothelium (CD105) within the lung
parenchyma. Scale bars, 50 mm. Misc=miscellaneous.
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Reticuloendothelial System
Responses in Fatal COVID-19
All cases showed a severe and stereotyped
pattern of immunologic changes, regardless
of viral RNA presence within the lymph
node or spleen (Figures 3H–3J). Within
the bone marrow, erythroid dysplasia,
plasma-cell excess with morphologic atypia,
and iron-storage abnormalities were
identified (Figures 3H and 3I, Figure E8,
and Table E4). A marked increase in the


































































































































Figure 2. Delineating pulmonary injury and vascular involvement in fatal coronavirus disease (COVID-19). (A) Detailed spatial evaluation of lung injury and
key pathologic abnormalities were determined within each lobe of lung for each patient (patients A–K) and compared with the presence or absence
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA by using multiplex PCR (*denotes invasive mechanical ventilation; n=11).
Representative images of organizing and exudative diffuse alveolar damage, pulmonary thrombus, bronchopneumonia, uninflamed lung, and variable
inflammation within the same lung. (B) In four individuals, frequent pulmonary vasculature immune infiltration was seen, with (C) multiplex immunofluorescence
defining these immune-cell populations (CD4, CD8 [T cells]; CD20 [B cells]; CD68 [macrophages]; MRP8 [neutrophils and myeloid lineage cells])
demonstrating MRP8 immunopositive mononuclear cells to be the predominant cell type (representative image, white stars denote vessel lumen and white
dashed line denotes elastic lamina). (D) Analysis of 50 arteries/arterioles from two selected patients quantifying cell types involved in vasculitis. Scale bars,
200 mm. DAD=diffuse alveolar damage; LLL= left lower lobe; LUL= left upper lobe; RLL= right lower lobe; RML= right middle lobe; RUL= right upper lobe.
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Figure 3. Pulmonary tissue and reticuloendothelial immune responses to fatal coronavirus disease (COVID-19). Regions of interest were defined
by histologic examination of hematoxylin and eosin–stained lung tissue to identify areas of diffuse alveolar damage in tissue from five patients.
(A) Representative image. Corresponding multiplex immunofluorescence was used to define vascular-endothelium populations (CD34) relative to immune-
cell populations: CD4, CD8 (T cells); CD20 (B cells); CD68 (macrophages); and MRP8 (neutrophils and myeloid lineage cells) (B) with and (C) without
autofluorescence. (D and E) Separate cell populations are highlighted. Immune-cell populations were quantified, with the (F) relative abundance of cell
types compared between COVID-19 (n=5) and normal, uninflamed lung from patients undergoing lung-cancer resection (n=4) and being (G) spatially
stratified into vascular/perivascular and parenchymal regions. (H) Key pathologic abnormalities within bone marrow included erythroid dysplasia, iron-
laden macrophages, and hemophagocytosis; plasma cells were confirmed by immunohistochemical staining and quantified in bone-marrow aspirates.
1 indicates present; 11 indicates frequent. (I) Representative image of bone marrow aspirate analysis demonstrating erythroid dysplasia (white arrows)
and frequent plasma cells (red arrows). (J) Mismatch between stereotyped plasma-cell abnormalities in the spleen and mediastinal LN (red) and
detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using multiplex PCR (green, positive; gray, negative). Scale bars, 200 mm.
LN= lymph node; P=parenchymal; V = vascular.
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seen in five of eight bone marrow aspirates,
but these plasma cells had a normal
phenotype on bone marrow trephines,
being negative for CD56 and cyclin D1,
and were polytypic with light-chain
immunohistochemistry (Figure E8).
Iron-laden macrophages were seen in all
but one case examined (7 of 8) and were
associated with abundant iron storage on
Perl’s stain. Although infrequent (1–2/1,000
cells), hemophagocytosis of erythroid
and/or myeloid precursors was present
in bone marrow in three cases. In
mediastinal lymph nodes, marked reactive
plasmacytosis of CD381/MUM11
and weakly CD1381 cells were seen in the
paracortex and medulla, again exhibiting
a degree of nuclear pleomorphism.
In the spleen, white-pulp atrophy was
common (4 of 7 cases), which is similar
to postmortem observations in fatal
SARS (23, 24). Splenic red pulp was
congested and, in all cases, contained an
increased number of plasma cells with
features similar to those observed in
mediastinal nodes.
Discussion
The data presented in this manuscript have
several implications for our understanding
of severe COVID-19. First, we show that
fatal COVID-19 is associated with variable
but widespread distribution of viral RNA
and protein but with an unexpected
discordant inflammatory response to
local viral presence, both between and
within tissues. If organ injury is primarily
collateral damage to an appropriate local
inflammatory response against SARS-CoV-2,
it would be expected to have a temporal and
spatial association with the presence of the
virus. We have observed the opposite. In
some cases, inflammation was present in
sections of lung without detectable virus
(and in patients who had not received
invasive mechanical ventilation). This could
relate to nonresolving inflammation after
viral clearance or to inflammation in areas of
the lung where viral replication had never
occurred; considering the sensitivity of PCR
for viral detection, we contend the latter is
possible. Conversely, even at the time of
death, up to 42 days after illness onset,
viral products (both RNA and protein)
and evidence of viral RNA synthesis
(subgenomic mRNA) could be detected in
numerous tissues but were dissociated from
host inflammatory responses. Furthermore,
the time from illness onset to death did
not correlate with the number of PCR-
confirmed SARS-CoV-2–positive organs.
The presence of viral RNA within the
kidney, intestine, and liver was not
associated with evidence of organ injury
or inflammation. By spatially resolving
viral presence, we confirmed that in
extrapulmonary tissues, cells containing
the SARS-CoV-2 S protein did not have
an adjacent localized cellular immune
response. These findings are consistent
with those related to strains of avian
coronavirus, which can replicate in the gut
without causing macroscopic or histologic
changes (25). Although lung tissue was
frequently highly abnormal, to our surprise,
the geographic distribution of SARS-CoV-2
RNA presence within the lung was not
linearly associated with either the presence
or the nature of the lung inflammatory
response. Within our cohort, we report
both DAD and bronchopneumonia in
sections of lung with and without detectable
virus, as well as viral presence without
inflammation. Together, these observations
on the immunopathology in relation to
SARS-CoV-2 reveal an aberrant immune
response, principally involving the lung and
reticuloendothelial system, that is not
clearly topologically associated with viral
presence. This is clinically relevant: the
evidence we present of virus-independent
immunopathology being a primary
mechanism underlying fatal COVID-19
supports the prioritization of tolerance as
a therapeutic strategy. This is consistent
with the beneficial effect of corticosteroids
in severe disease (13) and importantly
provides a potential biologic, mechanistic
basis for their efficacy, validating ongoing
investigations of immunomodulatory and
antiinflammatory drugs (26).
Second, we expand on the observation
of increased CD81 T cells and reduced
resident lung macrophages in BALF (15)
by describing a marked relative increase
in immune cells of the mononuclear
phagocyte lineage, and to a lesser extent
CD41 and CD81 T cells, within the
nonluminal pulmonary compartment.
Macrophage abnormalities were also seen
within bone marrow, with iron-laden
macrophages observed in all but one
patient, despite the absence of typical
causes of secondary iron overload
(transfusion, hemolysis), and this is
consistent with the observation that
circulating ferritin correlates with adverse
outcomes (11). In HIV and hepatitis C
virus infection, iron overload is associated
with a poor prognosis, with evidence
that viral infection itself may enhance
macrophage iron loading, further
suggesting that iron overload is an aberrant
macrophage response deleterious to the
host in COVID-19 (27).
Third, in results consistent with those
from emerging literature, we found that
small and large pulmonary vessel thrombi
were common in our series (28–30).
Thrombi in pulmonary vessels have also
been reported in fatal cases of SARS (23,
31), influenza A virus infection (32, 33),
and acute respiratory distress syndrome
more generally, but the frequency in
COVID-19 appears to be nearly a log order
higher than that of influenza and may be
due to distinct endothelial-injury pathways
(28), but the drivers of this are unknown.
Here, we describe an immune-cell
pulmonary arteritis in nearly half of our
cases, a novel pathologic process in severe
COVID-19 that may contribute to
endothelial-cell dysfunction and vascular
thrombosis and could represent a
therapeutic target. Phenotyping of this
pulmonary vasculitis revealed that the
primary immune cells are not infiltrating
T cells, in contrast to reports in fatal
influenza (28), but are instead MRP81
mononuclear cells infiltrating into vessel
walls. This COVID-19 vasculitis was not
associated with local endothelial viral
S-protein expression although S protein
was identified within a small number of
CD1051 endothelial cells in other vessels
within the lung. This observation validates
the drive to understand the immune
microenvironment at a whole-lung level
and is particularly interesting considering
the identification of proinflammatory
monocyte-derived macrophages in BALF
(15) and the recent report of C5aR11
macrophages associated with obliterating
arteritis in a COVID-19 autopsy sample,
implicating mononuclear phagocyte
activation and expansion as important
pathologic processes in COVID-19 (34).
Indeed, therapeutic targeting of the C5a
axis has been proposed (35). The
observation is also consistent with the
finding that the myeloid growth factor
GM-CSF (granulocyte–macrophage
colony–stimulating factor) and the
monocyte/macrophage chemoattractant
MCP-1 are elevated in blood and are
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associated with COVID-19 severity (36,
37). Going forward, it will be important to
clarify whether these macrophage
abnormalities, within inflamed pulmonary
vessels, lung parenchyma, and
reticuloendothelial tissues, have an antiviral
or tissue-repair role or whether, in being
activated as part of the wider immune
response to the virus, they are themselves
promoting vascular and tissue injury. The
implications for opposing strategies to
either boost or inhibit macrophage function
are obvious and necessitate urgent further
investigation.
Fourth, plasma-cell abnormalities in
the reticuloendothelial system and lung
provided further evidence of an aberrant
host response in fatal COVID-19. Although
plasma-cell expansion is expected to ensure
production of antibodies in the context of
acute infections, the degrees seen in our
study were extremely marked. Plasma cells
exhibited morphologic atypia but displayed
a reactive, polytypic phenotype. To some
extent, this correlates with peripheral blood
findings in patients with COVID-19, in
which CD41 and CD81 T-cell depletion is
characteristic but B-cell numbers are
maintained, with higher B-cell numbers
reported in severe cases (38, 39). The
plasma cells in our study were generally
MUM11 and CD381 but CD138
(syndecan)low/2, raising the possibility
that these are short-lived plasma cells
or are at a transitional or arrested stage
of development (40). In addition
to macrophage behavior and iron
accumulation, this identifies plasma cells
as a priority for future investigation of
therapeutic targets.
This report has several limitations. We
did not recruit patients without COVID-19
into our cohort, as this work was conducted
as an urgent investigation into COVID-19
rather than being conducted to describe how
COVID-19 differs from any other specific
pulmonary/systemic disease or infection.
Indeed, any immunopathologic changes in
COVID-19 that are shared with other causes
of severe pulmonary injury/inflammation
may still be avenues for therapeutic
intervention. Reports of histologic findings
in fatal influenza provide some comparison,
as discussed above in the context of
thrombosis, but we are unaware of a
similar depth of pulmonary parenchymal
immunophenotyping being reported. The
bone marrow B-cell and macrophage iron-
storage abnormalities reported here have
not been observed in fatal influenza andmay
therefore be unique to COVID-19 (41, 42).
The patient cohort is heterogeneous, in
particular with respect to age, receipt of
invasive mechanical ventilation (based on
clinical escalation decisions), and receipt of
experimental therapeutics (corticosteroids
and azithromycin). Although we were
unable to perform viral culture because
of biosafety requirements, we have
partly mitigated this by identifying and
sequencing reads unique to viral
subgenomic mRNA as an indicator of viral
RNA synthesis. Viral RNA detection was
performed by nonquantitative multiplex
PCR but we recognize that quantification of
viral load using quantitative RT-PCR would
yield potentially useful data. Finally,
the histopathologists assessing tissue
inflammation were not blinded to the
diagnosis of COVID-19.
Taken together, these data provide
comprehensive clinical, viral, and
immunologic profiling of severe COVID-19.
This highlights, for the first time, the
discrepancy between the presence of SARS-
CoV-2 and tissue inflammation. We
conclude that death in COVID-19 occurs
with a significant component of immune-
mediated, rather than pathogen-mediated
organ inflammation and injury. This is
consistent with the recent discovery that
immunosuppression with corticosteroids
prevents death in severe COVID-19,
supporting virus-independent
immunopathology being one of the
primary mechanisms underlying fatal
COVID-19. This suggests that better
understanding of noninjurious, organ-
specific viral tolerance mechanisms and
targeting of the dysregulated immune
response merit further investigation in
COVID-19. n
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